BioNxt Enters the Final Stretch Before Human Trials for Next-Generation MS Drug

Executive Summary

• BioNxt Solutions launched a 15‑day large‑mass animal dosing‑optimization study for its sublingual cladribine product BNT23001, the final pre‑clinical step before human bioequivalence trials slated for early 2026.
• The study aims to refine dose precision, assess comparative absorption versus the branded tablet, and generate data on potential super‑bioavailability that will guide the upcoming human trial design.
• Concurrently, the company reported favorable progress on international patent filings (Canada, Australia, EU, Eurasia, New Zealand, Japan, and a U.S. Track One priority), with intent‑to‑grant notices from the EPO and Eurasian Patent Office.

Key Details

• Study Design: 15‑day crossover dosing study in large‑mass animals (>40 kg) to fine‑tune sublingual drug load for humans.
• Timeline: Study start within two weeks of release; expected completion November 2025, results due December 2025.
• Objective: Generate comparative absorption data between BNT23001 (sublingual thin‑film) and standard oral cladribine tablets; inform human bioequivalence trial dosing strategy.
• Preclinical Findings to Date: Small‑mass animal trials (<20 kg) demonstrated bioequivalence and no toxicity; large‑mass study expected to confirm these results at a scale more predictive of human dosing.
• Human Trial Outlook: Comparative human bioequivalence study planned for early 2026, will directly measure drug absorption versus the branded tablet formulation.
• Patent Strategy: Ongoing nationalization across key markets (Canada, Australia, EU, Eurasia, New Zealand, Japan) plus a U.S. Track One priority filing; EPO and Eurasian Patent Office have issued intent‑to‑grant communications.
• CEO Comment: “The large‑mass animal study is expected to increase the formula precision in our human study… Optimization of drug load per dose and potential super bioavailability are key pieces of information that will guide the final clinical planning.” – Hugh Rogers, CEO.

Notable Quotes

“This large‑mass animal study is expected to increase the formula precision in our human study and is designed to generate comparative drug absorption results between the Company's sublingual formulation versus the name brand tablet formulation.” – Hugh Rogers, CEO, BioNxt Solutions Inc.